About Achieve Life Sciences (NASDAQ:ACHV)
Achieve Life Sciences, Inc., a biopharmaceutical company, develops and commercializes therapies that address treatment resistance in cancer patients. It is developing Apatorsen to block the production of heat shock protein 27, a cell-survival protein expressed in various types of cancers, including bladder, prostate, breast, pancreatic, and non-small cell lung cancer. The company is headquartered in Bothell, Washington.
Industry, Sector and Symbol
Industry Diagnostic substances
Sub-IndustryBiotechnology
SectorMedical
SymbolNASDAQ:ACHV
CUSIP68230A10
Phone425-686-1500
Debt
Debt-to-Equity RatioN/A
Current Ratio2.94%
Quick Ratio2.94%
Price-To-Earnings
Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A
Sales & Book Value
Annual Sales$5.06 million
Price / Sales3.40
Cash FlowN/A
Price / CashN/A
Book Value$0.66 per share
Price / Book2.05
Profitability
EPS (Most Recent Fiscal Year)N/A
Net Income$-10,580,000.00
Net MarginsN/A
Return on Equity-138.65%
Return on Assets-118.38%
Miscellaneous
Employees13
Outstanding Shares12,750,000
Achieve Life Sciences (NASDAQ:ACHV) Frequently Asked Questions
What is Achieve Life Sciences' stock symbol?
Achieve Life Sciences trades on the NASDAQ under the ticker symbol "ACHV."
How were Achieve Life Sciences' earnings last quarter?
Achieve Life Sciences (NASDAQ:ACHV) announced its quarterly earnings results on Thursday, March, 1st. The biopharmaceutical company reported ($0.32) earnings per share for the quarter. View Achieve Life Sciences' Earnings History.
When is Achieve Life Sciences' next earnings date?
Who are some of Achieve Life Sciences' key competitors?
Some companies that are related to Achieve Life Sciences include Egalet (EGLT), Biolase (BIOL), Vical (VICL), Cancer Genetics (CGIX), Microbot Medical (MBOT), ReWalk Robotics (RWLK), Actinium Pharmaceuticals (ATNM), Streamline Health Solutions (STRM), Cleveland BioLabs (CBLI), Surgical Innovations (SUN), OvaScience (OVAS), Kitov Pharma (KTOV), Jaguar Health (JAGX), Digirad (DRAD), Pernix Therapeutics (PTX), Innovus Pharmaceuticals (INNV), Neuralstem (CUR) and Concordia International (CXRX).
Who are Achieve Life Sciences' key executives?
Achieve Life Sciences' management team includes the folowing people:
- Mr. John A. Bencich M.B.A., Exec. VP, CFO, COO & Principal Accounting Officer (Age 41)
- Dr. Cindy Jacobs Ph.D., M.D., Exec. VP & Chief Medical Officer (Age 60)
- Dr. Richard A. B. Stewart, Chairman & CEO (Age 59)
- Dr. Anthony Clarke Ph.D., Pres, Chief Scientific Officer & Director (Age 62)
Has Achieve Life Sciences been receiving favorable news coverage?
Media coverage about ACHV stock has been trending somewhat positive this week, according to Accern Sentiment. The research group scores the sentiment of press coverage by reviewing more than 20 million news and blog sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Achieve Life Sciences earned a news impact score of 0.13 on Accern's scale. They also assigned news stories about the biopharmaceutical company an impact score of 46.88 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the stock's share price in the near future.
How do I buy shares of Achieve Life Sciences?
Shares of ACHV can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Achieve Life Sciences' stock price today?
One share of ACHV stock can currently be purchased for approximately $1.35.
How big of a company is Achieve Life Sciences?
Achieve Life Sciences has a market capitalization of $17.21 million and generates $5.06 million in revenue each year. Achieve Life Sciences employs 13 workers across the globe.
How can I contact Achieve Life Sciences?
Achieve Life Sciences' mailing address is 19820 NORTH CREEK PARKWAY, BOTHELL WA, 98011. The biopharmaceutical company can be reached via phone at 425-686-1500 or via email at [email protected]
MarketBeat Community Rating for Achieve Life Sciences (ACHV)
MarketBeat's community ratings are surveys of what our community members think about Achieve Life Sciences and other stocks. Vote "Outperform" if you believe ACHV will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ACHV will underperform the S&P 500 over the long term. You may vote once every thirty days.
Achieve Life Sciences (NASDAQ:ACHV) Analyst Ratings History
| Date | Brokerage | Action | Rating | Price Target | Impact on Share Price | Details |
|---|
(Data available from 4/21/2016 forward)
Achieve Life Sciences (NASDAQ:ACHV) Earnings History and Estimates Chart
Achieve Life Sciences (NASDAQ ACHV) Earnings History by Quarter
| Date | Quarter | Consensus Estimate | Actual EPS | Revenue Estimate | Actual Revenue | Release Link | Conference Call | Details |
|---|
| 5/21/2018 | | | | | | | | |
| 3/1/2018 | Q4 2017 | | ($0.32) | | | View | N/A |  |
| 11/9/2017 | Q3 2017 | | ($0.90) | | | View | N/A | |
| 7/31/2017 | Q2 2017 | | ($0.10) | | | View | N/A | |
| 5/15/2017 | Q1 2017 | ($0.29) | ($0.1120) | | | View | N/A | |
| 2/23/2017 | Q4 2016 | | ($2.09) | | | View | N/A | |
| 11/10/2016 | Q316 | ($0.26) | ($0.12) | | | View | N/A | |
| 8/4/2016 | Q216 | ($0.22) | ($0.23) | $1.17 million | $2.10 million | View | N/A | |
| 5/12/2016 | Q116 | ($0.12) | ($0.12) | $4.09 million | $2.90 million | View | Listen | |
| 3/9/2016 | Q4 | ($0.15) | ($0.06) | $6.00 million | $6.02 million | View | N/A | |
| 11/12/2015 | Q3 | ($0.17) | ($0.16) | $5.97 million | $6.74 million | View | Listen | |
| 8/13/2015 | Q2 | $0.34 | ($0.26) | $16.10 million | $4.03 million | View | Listen | |
| 5/14/2015 | Q115 | ($0.34) | ($0.20) | $4.66 million | $1.40 million | View | Listen | |
| 3/26/2015 | Q414 | ($0.30) | ($0.27) | $4.30 million | $5.70 million | View | N/A | |
| 10/30/2014 | | ($0.38) | ($0.23) | $4.69 million | $4.80 million | View | N/A | |
| 8/7/2014 | | ($0.55) | ($0.47) | $11.73 million | $4.93 million | View | N/A | |
| 4/30/2014 | | ($0.50) | ($0.59) | $8.68 million | $11.73 million | View | N/A | |
| 3/11/2014 | Q113 | ($0.66) | ($0.45) | $10.20 million | $8.60 million | View | N/A | |
| 11/7/2013 | Q3 2013 | ($7.59) | ($7.48) | $6.67 million | $9.86 million | View | N/A | |
| 8/8/2013 | Q2 2013 | ($6.93) | ($6.27) | $5.97 million | $6.34 million | View | N/A | |
| 5/2/2013 | Q1 2013 | ($7.48) | ($6.16) | $5.28 million | $5.08 million | View | N/A | |
| 3/7/2013 | Q4 2012 | ($5.39) | ($4.29) | | | View | N/A | |
| 11/8/2012 | Q312 | ($0.49) | ($0.40) | $4.52 million | $6.57 million | View | N/A | |
| 8/2/2012 | Q2 2012 | ($5.94) | ($3.19) | | | View | N/A | |
| 5/3/2012 | Q1 2012 | ($7.59) | ($5.86) | | | View | N/A | |
| 3/8/2012 | Q4 2011 | ($6.49) | ($10.79) | | | View | N/A | |
| 11/3/2011 | Q3 2011 | ($5.94) | ($4.90) | | | View | N/A | |
| 8/4/2011 | Q2 2011 | ($6.05) | ($7.39) | | | View | N/A | |
| 5/9/2011 | Q1 2011 | ($4.95) | ($5.82) | | | View | N/A | |
| 3/10/2011 | Q4 2010 | ($5.28) | $3.45 | | | View | N/A | |
| 11/4/2010 | Q3 2010 | ($5.17) | ($11.75) | | | View | N/A | |
| 8/5/2010 | Q2 2010 | ($4.95) | ($4.80) | | | View | N/A | |
| 5/6/2010 | Q1 2010 | ($4.95) | ($5.29) | | | View | N/A | |
| 3/8/2010 | Q4 2009 | $2.09 | ($7.04) | | | View | N/A | |
| 11/5/2009 | Q3 2009 | ($6.60) | ($4.35) | | | View | N/A | |
| 8/6/2009 | Q2 2009 | ($6.05) | ($9.04) | | | View | N/A | |
| 5/7/2009 | Q1 2009 | | ($4.77) | | | View | N/A | |
| 3/11/2009 | Q4 2008 | | ($10.89) | | | View | N/A | |
| 11/10/2008 | Q3 2008 | | $0.78 | | | View | N/A | |
| 3/5/2008 | Q4 2007 | ($53.42) | $10.29 | | | View | N/A | |
(Earnings results data provided by Zacks Investment Research)
Achieve Life Sciences (NASDAQ:ACHV) Dividend History by Quarter
| Announced | Period | Amount | Yield | Ex-Dividend Date | Record Date | Payable Date |
|---|
(Data available from 1/1/2013 forward)
Achieve Life Sciences (NASDAQ ACHV) Insider Trading and Institutional Ownership History
Insider Ownership Percentage: 35.80%
Institutional Ownership Percentage: 3.76%
Achieve Life Sciences (NASDAQ ACHV) Insider Trading History
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
| 8/19/2016 | John Bencich | CFO | Sell | 1,380 | $0.57 | $786.60 | 5,000 | |
| 6/13/2016 | Cindy Jacobs | CMO | Sell | 1,437 | $1.03 | $1,480.11 | 78,853 | |
| 6/13/2016 | Scott Daniel Cormack | CEO | Sell | 4,856 | $1.03 | $5,001.68 | 134,284 | |
| 3/15/2016 | Cindy Jacobs | CMO | Sell | 3,254 | $0.83 | $2,700.82 | 77,107 | |
| 3/15/2016 | John Bencich | CFO | Sell | 834 | $0.83 | $692.22 | 6,698 | |
| 3/15/2016 | Scott Daniel Cormack | CEO | Sell | 12,033 | $0.83 | $9,987.39 | 136,942 | |
| 8/18/2015 | John Bencich | CFO | Sell | 1,427 | $2.76 | $3,938.52 | 3,573 | |
| 6/12/2015 | Cindy Jacobs | CMO | Sell | 1,408 | $2.69 | $3,787.52 | | |
| 6/12/2015 | Scott Daniel Cormack | CEO | Sell | 4,571 | $2.69 | $12,295.99 | | |
| 5/20/2015 | Cindy Jacobs | CMO | Sell | 2,092 | $1.88 | $3,932.96 | | |
| 5/20/2015 | Scott Daniel Cormack | CEO | Sell | 7,543 | $1.88 | $14,180.84 | | |
| 8/13/2014 | Cindy Jacobs | CMO | Sell | 5,650 | $3.17 | $17,910.50 | | |
| 8/13/2014 | Scott Daniel Cormack | CEO | Sell | 18,341 | $3.17 | $58,140.97 | | |
| 3/17/2014 | Cindy Jacobs | CMO | Sell | 1,250 | $12.25 | $15,312.50 | 28,905 | |
| 3/17/2014 | Scott Daniel Cormack | CEO | Sell | 4,634 | $12.25 | $56,766.50 | 64,980 | |
| 8/19/2013 | Cindy Jacobs | CMO | Sell | 1,364 | $8.68 | $11,839.52 | 25,780 | |
| 8/19/2013 | Scott Daniel Cormack | CEO | Sell | 3,112 | $8.68 | $27,012.16 | 60,238 | |
| 3/12/2013 | Scott Daniel Cormack | CEO | Sell | 2,134 | $11.90 | $25,394.60 | 56,788 | |
| 8/15/2012 | Jack Goldstein | Director | Buy | 1,000 | $14.38 | $14,380.00 | | |
(Data available from 1/1/2013 forward)
Achieve Life Sciences (NASDAQ ACHV) News Headlines
| Source: |
|
| Date | Headline |
|---|
 | The 2017 Best Life Science Contract Research Organization (CRO), ChemPartner, Chooses CAS SciFinder® to ...
www.prnewswire.com - April 18 at 8:16 AM |
 | Galectin Therapeutics to Present at HC Wainwright Global Life Sciences Conference
globenewswire.com - April 4 at 8:20 AM |
 | Paratek Pharmaceuticals to Present at the HC Wainwright Annual Global Life Sciences Conference
www.nasdaq.com - March 28 at 8:27 AM |
 | Achieve Life Sciences Announces Cytisine Symposium at the 17th World Conference on Tobacco or Health
finance.yahoo.com - March 14 at 8:31 AM |
| This Morning's Technical Outlook on Biotech Stocks -- Acasti Pharma, Achieve Life Sciences, Actinium Pharma, and ... - PR Newswire (press release)
www.prnewswire.com - March 9 at 8:19 AM |
 | Achieve Life Sciences (ACHV) Issues Quarterly Earnings Results
www.americanbankingnews.com - March 2 at 11:39 AM |
| Achieve Announces Recent Highlights and Reports Year-End 2017 ... - PR Newswire (press release)
www.prnewswire.com - March 2 at 8:15 AM |
| Achieve Announces Recent Highlights and Reports Year-End 2017 Financial Results
finance.yahoo.com - March 1 at 5:52 PM |
| Head-To-Head Comparison: Achieve Life Sciences (ACHV) & TG Therapeutics (TGTX)
www.americanbankingnews.com - February 23 at 5:12 AM |
 | meltmedia Achieves Acquia Foundation Plus Partner Status
www.bizjournals.com - February 20 at 5:47 PM |
 | Achieve Life Sciences' cytisine shows encouraging effect in smoking cessation study; shares up 54%
seekingalpha.com - February 20 at 5:47 PM |
| Here’s Why Achieve Life Sciences Inc (ACHV) Jumped as Much as 54% Today
finance.yahoo.com - February 20 at 5:47 PM |
| Achieve Announces Preliminary Data from Cytisine Phase I/II Multi-Dose, Pharmacokinetic and Pharmacodynamics (PK/PD) Clinical Study
finance.yahoo.com - February 20 at 8:16 AM |
| Global Host Cell Contaminant Testing Market to Reach US$ 354 Mn by 2025 - Persistence Market Research
www.prnewswire.com - February 19 at 5:10 PM |
| Innovative Cancer Immunotherapy Company, Novelogics Biotechnology, Inc. adds Scott D. Cormack to the Board of Directors to Expand Strategic Growth Plans
finance.yahoo.com - February 13 at 9:49 AM |
| A Trader's View On Why Bigger Is (Usually) Better
finance.yahoo.com - February 2 at 3:47 PM |
| Achieve Life Sciences Making Progress in the Smoking Cessation Market, Recent Events
finance.yahoo.com - January 26 at 9:08 AM |
| What Does Achieve Life Sciences Inc’s (NASDAQ:ACHV) Ownership Structure Look Like?
finance.yahoo.com - January 24 at 8:07 AM |
| Achieve Announces Expansion of Partnership with the University of Bristol for Next Generation Cytisine-Based Therapies to Include Exclusive Rights for Cytisine Development Across Multiple Therapeutic Categories
finance.yahoo.com - January 24 at 8:07 AM |
| A Look At Achieve Life Sciences Inc (NASDAQ:ACHV) And The Healthcare Sector
finance.yahoo.com - January 2 at 7:34 PM |
| Achieve Announces Clinical Trial Supply and Cooperation Agreement with the University of Auckland for the Evaluation of Cytisine Compared to Varenicline for Smoking Cessation
finance.yahoo.com - December 7 at 6:28 PM |
| ValuEngine Upgrades OncoGenex Pharmaceuticals (ACHV) to Sell
www.americanbankingnews.com - December 4 at 11:10 PM |
| OncoGenex Pharmaceuticals Inc. (ACHV) Announces Earnings Results
www.americanbankingnews.com - November 10 at 12:51 PM |
| Critical Survey: OncoGenex Pharmaceuticals (ACHV) & The Competition
www.americanbankingnews.com - November 10 at 3:10 AM |
| Achieve Reports Financial Results for Third Quarter 2017
finance.yahoo.com - November 9 at 4:24 PM |
| Achieve to Present at the 29th Annual Piper Jaffray Healthcare Conference on November 28th, 2017
finance.yahoo.com - November 8 at 5:23 PM |
| Achieve Announces Availability of Company Presentation from the Virtual Investor Conference
finance.yahoo.com - November 6 at 4:09 PM |
| Financial Contrast: OncoGenex Pharmaceuticals (ACHV) and The Competition
www.americanbankingnews.com - November 3 at 1:10 PM |
| Achieve Announces Company Presentation at Virtual Investor Conference on November 2, 2017
finance.yahoo.com - October 30 at 3:29 PM |
| Achieve Announces Exclusive, Long-term Manufacturing Agreement with Sopharma for Clinical and Commercial Supply of Cytisine
finance.yahoo.com - October 26 at 11:35 AM |
| CASI Pharmaceuticals (CASI) and OncoGenex Pharmaceuticals (ACHV) Critical Review
www.americanbankingnews.com - October 26 at 1:16 AM |
| Head to Head Review: OncoGenex Pharmaceuticals (ACHV) & The Competition
www.americanbankingnews.com - October 24 at 12:30 PM |
| Achieve Announces Advancement of Cytisine Clinical Development Program
finance.yahoo.com - October 4 at 8:09 AM |
 | BioAlberta Recognizes Alberta Innovators and Entrepreneurs at 2017 AGM and Awards Gala - Business Wire (press release)
www.businesswire.com - September 23 at 8:40 PM |
| Achieve Announces Share Purchase Agreement with Lincoln Park Capital Fund, LLC
finance.yahoo.com - September 14 at 8:24 PM |
| Achieve Announces Initiation of Cytisine Clinical Development Program
finance.yahoo.com - August 16 at 3:24 PM |
| Albany Molecular Research (AMRI) & OncoGenex Pharmaceuticals (ACHV) Critical Comparison
www.americanbankingnews.com - August 15 at 6:08 PM |
| Achieve Announces FDA Acceptance of the Investigational New Drug Application (IND) for Cytisine as a Smoking Cessation Treatment
finance.yahoo.com - August 10 at 4:51 PM |
 | Affirmative Action Battle Has a New Focus: Asian-Americans - The ... - New York Times
www.nytimes.com - August 4 at 12:47 PM |
Achieve Life Sciences (NASDAQ:ACHV) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Achieve Life Sciences (NASDAQ:ACHV) Income Statement, Balance Sheet and Cash Flow Statement
Achieve Life Sciences (NASDAQ ACHV) Stock Chart for Saturday, April, 21, 2018
Loading chart…
